Showing 5621-5630 of 9527 results for "".
Advances in the Treatment of Reticular Erythematous Mucinosis
https://practicaldermatology.com/youngmd-connect/resident-resource-center/advances-in-the-treatment-of-reticular-erythematous-mucinosis/23491/Considering nicotinamide’s anti-inflammatory properties for inflammatory dermatological conditions to avoid steroid and antibiotic overuse.Choosing a Systemic Treatment for Elderly Patients with Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/choosing-a-systemic-treatment-for-elderly-patients-with-atopic-dermatitis/60990/These findings challenge long-held fears about using systemic agents in the elderly population.Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis
https://practicaldermatology.com/programs/cme/test-your-skills-and-learn-from-experts-on-il-13-inhibitors-in-moderate-to-severe-atopic-dermatitis/37624/Watch an expert-led case discussion on the role of IL-13 in moderate to severe atopic dermatitis and the efficacy on its inhibition through biologic therapies to achieve control.The Microbiome in Acne: Where are We Now?
https://practicaldermatology.com/topics/acne-rosacea/the-microbiome-in-acne-where-are-we-now/23731/As research reveals connections of the microbiome to skin disease, clinicians may discover new approaches to managing the disease.Study Highlights Top-Rated Dermatology Education Apps
https://practicaldermatology.com/topics/practice-management/study-highlights-top-rated-dermatology-education-apps/23565/Researchers rated apps based on four key features.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muComorbidities in Atopic Dermatitis
https://practicaldermatology.com/issues/october-2025/comorbidities-in-atopic-dermatitis/39756/In this article, as part of a series on comorbidities associated with immune-mediated skin diseases, we explore the spectrum of comorbidities linked to AD.Staphylococcus aureus Colonization
https://practicaldermatology.com/issues/september-2025/staphylococcus-aureus-colonization/37626/In a recent review article, Piewngam and Otto examined the epidemiology, mechanisms, and clinical implications of Staphylococcus aureus (S. aureus) colonization, while evaluating both current and emerging strategies for decolonization.Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/annual-trends-in-medicare-part-d-prescription-claims-for-guselkumab-20182020/28861/Jachin Wu, MD, FAAD, and colleagues talk about Medicare claims for guselkumabCollagen in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/collagen-atopic-dermatitis/27167/Kripa Ahuja, MS, and Peter Lio, MD, review a 2024 study from Szalsus et al. looking at the role of collagens in atopic dermatitis (AD).